Učitavanje...
Glucose-lowering therapy in type 2 diabetes: New hope after the EMPA-REG outcome trial
Prevention of cardiovascular morbidity and mortality remains the key factor in the treatment of type 2 diabetes (T2DM). In the early phase of T2DM, multifactorial intervention is mandatory and glucose levels should be near normal, in particular in younger patients presenting with the highest cardiov...
Spremljeno u:
Izdano u: | Herz |
---|---|
Glavni autori: | , |
Format: | Artigo |
Jezik: | Inglês |
Izdano: |
Springer Medizin
2016
|
Teme: | |
Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4839058/ https://ncbi.nlm.nih.gov/pubmed/27071968 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00059-016-4427-3 |
Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|